List of EGFR inhibitors (anti-EGFR) - Drugs.com
Epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it.
Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery ...
EGFR tyrosine kinase activity inhibition is considered a promising therapeutic strategy for the treatment of cancer. Many small-molecule inhibitors of EGFR tyrosine kinase (EGFR-TK), from medicinally privileged molecules to commercial drugs, have been overviewed.
Third-generation EGFR and ALK inhibitors: mechanisms of
2022年5月9日 · Numerous EGFR and ALK tyrosine kinase inhibitors (TKIs) with demonstrated efficacy in patients with EGFR -mutant and ALK -rearranged NSCLCs have been developed, culminating in the availability...
Globally Approved EGFR Inhibitors: Insights into Their Syntheses …
2021年11月4日 · In this review, we focus on the EGFR small-molecule inhibitors that have been approved for clinical uses in cancer therapy. These drugs are classified based on their chemical structures, target kinases, and pharmacological uses. …
EGFR Inhibitors - an overview | ScienceDirect Topics
EGFR inhibitors are a class of antineoplastic drugs that includes gefitnib, cetuximab, erlotinib, and trastuzumab. EGFR inhibitors are commonly used in the treatment of carcinomas of the lung, breast, and colon.
Globally Approved EGFR Inhibitors: Insights into Their Syntheses ...
2021年11月4日 · In this review, we focus on the EGFR small-molecule inhibitors that have been approved for clinical uses in cancer therapy. These drugs are classified based on their chemical structures, target kinases, and pharmacological uses. …
Toward the next generation EGFR inhibitors: an overview of …
2023年4月11日 · We also review the proposed therapeutic strategies for each type of mutation conferring resistance to osimertinib and give an outlook to the development of the next generation EGFR inhibitors.
Review on EGFR Inhibitors: Critical Updates - PubMed
EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade.
EGFR Antagonists in Cancer Treatment | New England Journal of …
2008年3月13日 · After 20 years of drug development, four EGFR antagonists are currently available for the treatment of four metastatic epithelial cancers: non–small-cell lung cancer, squamous-cell carcinoma of...
EGFR Inhibitors: Toxicities and Strategies - Medscape Education
5 天之前 · Evidence-based practice for the unique side effects associated with EGFR inhibitors is still evolving. This review will enable clinicians to understand the mechanisms underlying EGFR inhibition, identify currently approved EGFR inhibitors, and recognize potential adverse effects.